These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37162602)

  • 21. Risk of new-onset urinary incontinence 3 and 12 months after vaginal or cesarean delivery of twins: Part I.
    de Tayrac R; Béchard F; Castelli C; Alonso S; Vintejoux E; Goffinet F; Letouzey V; Schmitz T
    Int Urogynecol J; 2019 Jun; 30(6):881-891. PubMed ID: 30293167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective study of pelvic floor dysfunctions related to delivery.
    Torrisi G; Minini G; Bernasconi F; Perrone A; Trezza G; Guardabasso V; Ettore G
    Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):110-5. PubMed ID: 22093192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors.
    Wang TF; Clarke AE; Awan AA; Tanuseputro P; Carrier M; Sood MM
    JAMA Netw Open; 2022 Jun; 5(6):e2219128. PubMed ID: 35763294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer.
    Baumgart J; Nilsson K; Stavreus-Evers A; Kask K; Villman K; Lindman H; Kallak T; Sundström-Poromaa I
    Am J Obstet Gynecol; 2011 Jan; 204(1):26.e1-7. PubMed ID: 20950790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis.
    Yu Q; Xu Y; Yu E; Zheng Z
    J Clin Pharm Ther; 2022 May; 47(5):575-587. PubMed ID: 34984740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
    ; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M
    Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perinatal incontinence: Psychometric evaluation of the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form and Wexner Scale.
    Slavin V; Gamble J; Creedy DK; Fenwick J
    Neurourol Urodyn; 2019 Nov; 38(8):2209-2223. PubMed ID: 31385364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
    Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
    JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of life and the prevalence of urinary incontinence after surgical treatment for gynecologic cancer: a questionnaire survey.
    Nakayama N; Tsuji T; Aoyama M; Fujino T; Liu M
    BMC Womens Health; 2020 Jul; 20(1):148. PubMed ID: 32680500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of exercise on physical outcomes of breast cancer survivors receiving hormone therapy - A systematic review and meta-analysis.
    Boing L; Vieira MCS; Moratelli J; Bergmann A; Guimarães ACA
    Maturitas; 2020 Nov; 141():71-81. PubMed ID: 33036706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
    Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ;
    J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
    Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
    Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
    Montagna E; Cancello G; Colleoni M
    Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
    Roberts KE; Rickett K; Feng S; Vagenas D; Woodward NE
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012988. PubMed ID: 31994181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
    Morales L; Neven P; Timmerman D; Christiaens MR; Vergote I; Van Limbergen E; Carbonez A; Van Huffel S; Ameye L; Paridaens R
    Anticancer Drugs; 2004 Sep; 15(8):753-60. PubMed ID: 15494636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
    Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer.
    Bicer T; Imamoglu GI; Dogan AS; Avarisli NA; Kabatas N; Bicer BK; Gurdal C
    Int Ophthalmol; 2020 Aug; 40(8):2077-2083. PubMed ID: 32333340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.